BMS Signs an Exclusive Global License with Agenus for its Anti-TIGIT Bispecific Antibody Program

Shots:

Agenus to receive a $200M as up front & ~$1.36B as development, regulatory and commercial milestones plus royalties on net sales of the therapies. Agenus will retain options to conduct clinical studies and combination studies with other pipeline assets and to co-promote AGEN1777 in the US
BMS will be solely responsible for the development & commercialization of AGEN1777 and its related products globally
Agenus expects to file an IND to the US FDA for AGEN1777 in Q2’21. BMS intends to advance the research and development of AGEN1777 in immuno-oncology for tumor indications including NSCLC

Click here to read full press release/ article | Ref: GLOBE NEWSWIRE | Image: PRNewswire